How much funding has Veralox Therapeutics raised?

Veralox Therapeutics has raised $46.0M in total funding, most recently a Seed round.

Who are Veralox Therapeutics's investors?

Veralox Therapeutics's investors include JDRF T1D Fund, Sanofi Ventures, Pappas Capital, Hatteras Venture Partners, Maryland Momentum Fund, Alexandria Venture Investments.

When was Veralox Therapeutics founded?

Veralox Therapeutics was founded in 2018.

Where is Veralox Therapeutics headquartered?

Veralox Therapeutics is headquartered in FREDERICK, United States.

What industry is Veralox Therapeutics in?

Veralox Therapeutics operates in Biotech, Healthcare.

How many employees does Veralox Therapeutics have?

Veralox Therapeutics has 11-50 employees.

Veralox Therapeutics

FREDERICK, United States · Founded 2018 · $46.0M raised

Biotech

Healthcare

Headquarters: FREDERICK
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: veralox.com
Total Funding: $46.0M
Last Round: $5.4M SeedJun 2023
Rounds: 3

About

Veralox Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics targeting the 12-lipoxygenase (12-LOX) and cGAS pathways to treat immuno-inflammatory, metabolic, and oncological diseases. Its lead candidate, VLX-1005, is a 12-LOX inhibitor being studied for heparin-induced thrombocytopenia, with favorable Phase 1 results reported in 2022. In January 2025 the company expanded its pipeline through an exclusive option to acquire Nudge Therapeutics' preclinical cGAS inhibitor compounds, broadening its inflammatory and autoimmune disease programs.

Summary

Veralox Therapeutics is a Biotech company based in FREDERICK, United States, founded in 2018. It has raised $46.0M in total across 3 rounds, most recently a $5.4M Seed round in Jun 2023. Investors include JDRF T1D Fund, Sanofi Ventures and Pappas Capital.